Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the acute leukemia working party of the EBMT

Bhagirathbhai Dholaria; Bipin N Savani; Myriam Labopin; Leo Luznik; Annalisa Ruggeri; Stephan Mielke; Monzr M Al Malki; Piyanuch Kongtim; Ephraim Fuchs; Xiao-Jun Huang; Franco Locatelli; Franco Aversa; Luca Castagna; Andrea Bacigalupo; Massimo Martelli; Didier Blaise; Patrick Ben Soussan; Yolande Arnault; Rupert Handgretinger; Denis-Claude Roy; Paul O'Donnell; Asad Bashey; Scott Solomon; Rizwan Romee; Philippe Lewalle; Jorge Gayoso; Michael Maschan; Hillard M Lazarus; Karen Ballen; Sebastian Giebel; Frederic Baron; Fabio Ciceri; Jordi Esteve; Norbert-Claude Gorin; Alexandros Spyridonidis; Christoph Schmid; Stefan O Ciurea; Arnon Nagler; Mohamad Mohty

doi:10.3324/haematol.2019.219790

Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the acute leukemia working party of the EBMT

Bhagirathbhai Dholaria, Bipin N Savani, Myriam Labopin, Leo Luznik, Annalisa Ruggeri, Stephan Mielke, Monzr M Al Malki, Piyanuch Kongtim, Ephraim Fuchs, Xiao-Jun Huang, Franco Locatelli, Franco Aversa, Luca Castagna, Andrea Bacigalupo, Massimo Martelli, Didier Blaise, Patrick Ben Soussan, Yolande Arnault, Rupert Handgretinger, Denis-Claude RoyPaul O'Donnell, Asad Bashey, Scott Solomon, Rizwan Romee, Philippe Lewalle, Jorge Gayoso, Michael Maschan, Hillard M Lazarus, Karen Ballen, Sebastian Giebel, Frederic Baron, Fabio Ciceri, Jordi Esteve, Norbert-Claude Gorin, Alexandros Spyridonidis, Christoph Schmid, Stefan O Ciurea, Arnon Nagler, Mohamad Mohty

Research output: Contribution to journal › Article › peer-review

Abstract

Donor lymphocyte infusion has been used in the management of relapsed disease hematological malignancies after allogeneic hematopoietic cell transplantation. It can eradicate minimal residual disease or be used to rescue a hematological relapse, being able to induce durable remissions in a subset of patients. With the increased in the use of haploidentical hematopoietic cell transplantation, there is renewed interest in the use of donor lymphocytes to either treat or prevent disease relapse post-transplant. Published retrospective and small prospective studies have shown encouraging results with therapeutic donor lymphocyte infusion in different haploidentical transplantation platforms. In this consensus paper, finalized on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we summarized the available evidence on the use of donor lymphocyte infusion from haploidentical donor and provide recommendations on its therapeutic, pre-emptive and prophylactic use in clinical practice.

Original language	English
Journal	Haematologica
DOIs	https://doi.org/10.3324/haematol.2019.219790
Publication status	Published - Sep 19 2019

Access to Document

10.3324/haematol.2019.219790

Cite this

Dholaria, B., Savani, B. N., Labopin, M., Luznik, L., Ruggeri, A., Mielke, S., Al Malki, M. M., Kongtim, P., Fuchs, E., Huang, X-J., Locatelli, F., Aversa, F., Castagna, L., Bacigalupo, A., Martelli, M., Blaise, D., Ben Soussan, P., Arnault, Y., Handgretinger, R., ... Mohty, M. (2019). Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the acute leukemia working party of the EBMT. Haematologica. https://doi.org/10.3324/haematol.2019.219790

Dholaria, B, Savani, BN, Labopin, M, Luznik, L, Ruggeri, A, Mielke, S, Al Malki, MM, Kongtim, P, Fuchs, E, Huang, X-J, Locatelli, F, Aversa, F, Castagna, L , Bacigalupo, A, Martelli, M, Blaise, D, Ben Soussan, P, Arnault, Y, Handgretinger, R, Roy, D-C, O'Donnell, P, Bashey, A, Solomon, S, Romee, R, Lewalle, P, Gayoso, J, Maschan, M, Lazarus, HM, Ballen, K, Giebel, S, Baron, F, Ciceri, F, Esteve, J, Gorin, N-C, Spyridonidis, A, Schmid, C, Ciurea, SO, Nagler, A & Mohty, M 2019, 'Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the acute leukemia working party of the EBMT', Haematologica. https://doi.org/10.3324/haematol.2019.219790

@article{254c2843c01a45cbae8f90e99f7eafbc,

title = "Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the acute leukemia working party of the EBMT",

abstract = "Donor lymphocyte infusion has been used in the management of relapsed disease hematological malignancies after allogeneic hematopoietic cell transplantation. It can eradicate minimal residual disease or be used to rescue a hematological relapse, being able to induce durable remissions in a subset of patients. With the increased in the use of haploidentical hematopoietic cell transplantation, there is renewed interest in the use of donor lymphocytes to either treat or prevent disease relapse post-transplant. Published retrospective and small prospective studies have shown encouraging results with therapeutic donor lymphocyte infusion in different haploidentical transplantation platforms. In this consensus paper, finalized on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we summarized the available evidence on the use of donor lymphocyte infusion from haploidentical donor and provide recommendations on its therapeutic, pre-emptive and prophylactic use in clinical practice.",

author = "Bhagirathbhai Dholaria and Savani, {Bipin N} and Myriam Labopin and Leo Luznik and Annalisa Ruggeri and Stephan Mielke and {Al Malki}, {Monzr M} and Piyanuch Kongtim and Ephraim Fuchs and Xiao-Jun Huang and Franco Locatelli and Franco Aversa and Luca Castagna and Andrea Bacigalupo and Massimo Martelli and Didier Blaise and {Ben Soussan}, Patrick and Yolande Arnault and Rupert Handgretinger and Denis-Claude Roy and Paul O'Donnell and Asad Bashey and Scott Solomon and Rizwan Romee and Philippe Lewalle and Jorge Gayoso and Michael Maschan and Lazarus, {Hillard M} and Karen Ballen and Sebastian Giebel and Frederic Baron and Fabio Ciceri and Jordi Esteve and Norbert-Claude Gorin and Alexandros Spyridonidis and Christoph Schmid and Ciurea, {Stefan O} and Arnon Nagler and Mohamad Mohty",

note = "Copyright {\textcopyright} 2019, Ferrata Storti Foundation.",

year = "2019",

month = sep,

day = "19",

doi = "10.3324/haematol.2019.219790",

language = "English",

journal = "Haematologica",

issn = "0390-6078",

publisher = "NLM (Medline)",

}

TY - JOUR

T1 - Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor

T2 - consensus recommendations from the acute leukemia working party of the EBMT

AU - Dholaria, Bhagirathbhai

AU - Savani, Bipin N

AU - Labopin, Myriam

AU - Luznik, Leo

AU - Ruggeri, Annalisa

AU - Mielke, Stephan

AU - Al Malki, Monzr M

AU - Kongtim, Piyanuch

AU - Fuchs, Ephraim

AU - Huang, Xiao-Jun

AU - Locatelli, Franco

AU - Aversa, Franco

AU - Castagna, Luca

AU - Bacigalupo, Andrea

AU - Martelli, Massimo

AU - Blaise, Didier

AU - Ben Soussan, Patrick

AU - Arnault, Yolande

AU - Handgretinger, Rupert

AU - Roy, Denis-Claude

AU - O'Donnell, Paul

AU - Bashey, Asad

AU - Solomon, Scott

AU - Romee, Rizwan

AU - Lewalle, Philippe

AU - Gayoso, Jorge

AU - Maschan, Michael

AU - Lazarus, Hillard M

AU - Ballen, Karen

AU - Giebel, Sebastian

AU - Baron, Frederic

AU - Ciceri, Fabio

AU - Esteve, Jordi

AU - Gorin, Norbert-Claude

AU - Spyridonidis, Alexandros

AU - Schmid, Christoph

AU - Ciurea, Stefan O

AU - Nagler, Arnon

AU - Mohty, Mohamad

PY - 2019/9/19

Y1 - 2019/9/19

N2 - Donor lymphocyte infusion has been used in the management of relapsed disease hematological malignancies after allogeneic hematopoietic cell transplantation. It can eradicate minimal residual disease or be used to rescue a hematological relapse, being able to induce durable remissions in a subset of patients. With the increased in the use of haploidentical hematopoietic cell transplantation, there is renewed interest in the use of donor lymphocytes to either treat or prevent disease relapse post-transplant. Published retrospective and small prospective studies have shown encouraging results with therapeutic donor lymphocyte infusion in different haploidentical transplantation platforms. In this consensus paper, finalized on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we summarized the available evidence on the use of donor lymphocyte infusion from haploidentical donor and provide recommendations on its therapeutic, pre-emptive and prophylactic use in clinical practice.

AB - Donor lymphocyte infusion has been used in the management of relapsed disease hematological malignancies after allogeneic hematopoietic cell transplantation. It can eradicate minimal residual disease or be used to rescue a hematological relapse, being able to induce durable remissions in a subset of patients. With the increased in the use of haploidentical hematopoietic cell transplantation, there is renewed interest in the use of donor lymphocytes to either treat or prevent disease relapse post-transplant. Published retrospective and small prospective studies have shown encouraging results with therapeutic donor lymphocyte infusion in different haploidentical transplantation platforms. In this consensus paper, finalized on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we summarized the available evidence on the use of donor lymphocyte infusion from haploidentical donor and provide recommendations on its therapeutic, pre-emptive and prophylactic use in clinical practice.

U2 - 10.3324/haematol.2019.219790

DO - 10.3324/haematol.2019.219790

M3 - Article

JO - Haematologica

JF - Haematologica

SN - 0390-6078

ER -

Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the acute leukemia working party of the EBMT

Abstract

Access to Document

Fingerprint

Cite this